Oct 21 (Reuters) - Laboratorios Farmaceuticos ROVI SA ROVI.MC:
TO COLLABORATE WITH ROCHE ON NEW DRUG MANUFACTURING
NEW MEDICINE, CURRENTLY IN CLINICAL DEVELOPMENT, IS FROM ROCHE'S METABOLIC AND CARDIOVASCULAR PORTFOLIO
PARTIES INTEND TO SIGN THE FINAL AGREEMENT IN THE COMING DAYS
FOR 2030, ROVI ESTIMATES AGREEMENT WILL CONTRIBUTE TO MINIMUM INCREASE OF 20% TO 25% IN CONTRACT MANUFACTURING BUSINESS SALES COMPARED WITH 2024
Source text: nCNMbQdM1B
Further company coverage: ROVI.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))